Health care stocks were higher before Friday's opening bell, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.5% and the iShares Biotechnology ETF (IBB) advancing 0.2%.

Trevi Therapeutics (TRVI) shares were down more than 6% before market open. The company said late Thursday it priced its public offering of 11.6 million common shares at $13 each for about $150 million in gross proceeds.

Gilead Sciences (GILD) said Friday it has received all the regulatory approvals required for its previously announced acquisition of Arcellx. The company's shares were nearly 1% higher.

Kura Oncology (KURA) stock rose 8% before market open after the company said that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.